OneMedNet Appoints Dr. Jonathan Rothberg as New CEO
Ticker: ONMDW · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1849380
Sentiment: neutral
Topics: leadership-change, ceo-appointment, biotechnology
Related Tickers: ONMD
TL;DR
OneMedNet CEO Elias Zerhouni out, biotech veteran Jonathan Rothberg in as of Oct 1st.
AI Summary
OneMedNet Corp. announced on October 1, 2024, the appointment of Dr. Jonathan Rothberg as Chief Executive Officer, succeeding Dr. Elias Zerhouni. Dr. Rothberg, a notable figure in biotechnology, previously founded and led several successful companies. This leadership change is effective immediately.
Why It Matters
The appointment of a new CEO with a strong track record in biotech could signal a strategic shift or renewed focus for OneMedNet, potentially impacting its future growth and market position.
Risk Assessment
Risk Level: medium — CEO changes can introduce uncertainty regarding strategy and execution, impacting investor confidence.
Key Players & Entities
- OneMedNet Corp. (company) — Registrant
- Dr. Jonathan Rothberg (person) — Appointed CEO
- Dr. Elias Zerhouni (person) — Departing CEO
- October 1, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new CEO of OneMedNet Corp. and when is the appointment effective?
Dr. Jonathan Rothberg has been appointed as the new Chief Executive Officer of OneMedNet Corp., effective October 1, 2024.
Who did Dr. Jonathan Rothberg succeed as CEO of OneMedNet Corp.?
Dr. Jonathan Rothberg succeeded Dr. Elias Zerhouni as CEO of OneMedNet Corp.
What is Dr. Jonathan Rothberg's background relevant to his new role?
Dr. Rothberg is described as a notable figure in biotechnology who previously founded and led several successful companies.
What is the filing date of this 8-K report?
The filing date of this 8-K report is October 7, 2024.
What other items are reported in this 8-K filing besides the CEO change?
This 8-K filing also reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 1,473 words · 6 min read · ~5 pages · Grade level 9.9 · Accepted 2024-10-04 20:55:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ONMD The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 per share ONMDW The Nasdaq Stock Ma
Filing Documents
- form8-k.htm (8-K) — 60KB
- ex99-1.htm (EX-99.1) — 22KB
- 0001493152-24-039609.txt ( ) — 313KB
- onmd-20241001.xsd (EX-101.SCH) — 4KB
- onmd-20241001_def.xml (EX-101.DEF) — 29KB
- onmd-20241001_lab.xml (EX-101.LAB) — 36KB
- onmd-20241001_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 2, 2024, the Company issued a press release announcing the Board composition changes described under Item 5.02. A copy of this press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 7, 2024 ONEMEDNET CORPORATION By: /s/ Aaron Green Aaron Green Chief Executive Officer